ALK and non-small cell lung carcinoma: Inhibiting EML4-ALK using Alectinib or Lorlatinib resulted in a similar mTOR, p70S6 and ULK1 phosphorylation pattern as seen with Ceritinib treatment (Supplementary Fig. 1C–D).These results suggest that ALK inhibition reduces mTOR activity in H3122 EML4-ALK+ NSCLC cells, and that this leads to activation of ULK1 (via removal of the inhibitory phosphate group at Serine 757), which in turn may lead to initiation of macroautophagy.